Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 237

1.

Amyloid beta 1-42 and tau in the cerebrospinal fluid of renal failure patients for the diagnosis of Alzheimer's disease.

Shea YF, Chu LW, Mok MY, Lam MF.

J Nephrol. 2014 Apr;27(2):217-20. doi: 10.1007/s40620-014-0043-6. Epub 2014 Jan 29.

PMID:
24473733
2.

Assessment of cerebrospinal fluid (CSF) beta-amyloid (1-42), phosphorylated tau (ptau-181) and total Tau protein in patients with Alzheimer's disease (AD) and other dementia at Siriraj Hospital, Thailand.

Thaweepoksomboon J, Senanarong V, Poungvarin N, Chakorn T, Siwasariyanon N, Washirutmangkur L, Udompunthuruk S.

J Med Assoc Thai. 2011 Feb;94 Suppl 1:S77-83.

PMID:
21721431
3.

Cerebrospinal fluid biomarkers of Alzheimer's disease in Chinese patients: a pilot study.

Shea YF, Chu LW, Zhou L, Li WM, Lin OY, Chan MN, Xu A, Wong R, Ho TY, Liu KW, Ha J, Daniel TW, Song YQ, Lam KS.

Am J Alzheimers Dis Other Demen. 2013 Dec;28(8):769-75. doi: 10.1177/1533317513504615. Epub 2013 Oct 1.

PMID:
24085246
4.

Comparison between clinical diagnosis and CSF biomarkers of Alzheimer disease in elderly patients with late onset psychosis: Helsinki Old Age Psychosis Study (HOPS).

Seppälä TT, Louhija UM, Appelberg B, Herukka SK, Juva K.

Am J Geriatr Psychiatry. 2014 Sep;22(9):908-16. doi: 10.1016/j.jagp.2012.08.020. Epub 2013 Apr 15.

PMID:
23597931
5.

The impact of cerebrospinal fluid biomarkers on the diagnosis of Alzheimer's disease.

Engelborghs S, Le Bastard N.

Mol Diagn Ther. 2012 Jun 1;16(3):135-41. doi: 10.2165/11634170-000000000-00000.

PMID:
22646065
6.

Cystatin C levels are positively correlated with both Abeta42 and tau levels in cerebrospinal fluid in persons with Alzheimer's disease, mild cognitive impairment, and healthy controls.

Sundelöf J, Sundström J, Hansson O, Eriksdotter-Jönhagen M, Giedraitis V, Larsson A, Degerman-Gunnarsson M, Ingelsson M, Minthon L, Blennow K, Kilander L, Basun H, Lannfelt L.

J Alzheimers Dis. 2010;21(2):471-8. doi: 10.3233/JAD-2010-091594.

PMID:
20555147
7.

Cerebrospinal fluid phospho-tau, total tau and beta-amyloid(1-42) in the differentiation between Alzheimer's disease and vascular dementia.

Nägga K, Gottfries J, Blennow K, Marcusson J.

Dement Geriatr Cogn Disord. 2002;14(4):183-90.

PMID:
12411760
8.

Association between CSF biomarkers and incipient Alzheimer's disease in patients with mild cognitive impairment: a follow-up study.

Hansson O, Zetterberg H, Buchhave P, Londos E, Blennow K, Minthon L.

Lancet Neurol. 2006 Mar;5(3):228-34. Erratum in: Lancet Neurol. 2006 Apr;5(4):293.

PMID:
16488378
9.

Cerebrospinal fluid Aβ1-40 improves differential dementia diagnosis in patients with intermediate P-tau181P levels.

Slaets S, Le Bastard N, Martin JJ, Sleegers K, Van Broeckhoven C, De Deyn PP, Engelborghs S.

J Alzheimers Dis. 2013;36(4):759-67. doi: 10.3233/JAD-130107.

PMID:
23666174
10.

Cerebrospinal fluid levels of total-tau, phospho-tau and A beta 42 predicts development of Alzheimer's disease in patients with mild cognitive impairment.

Andreasen N, Vanmechelen E, Vanderstichele H, Davidsson P, Blennow K.

Acta Neurol Scand Suppl. 2003;179:47-51.

PMID:
12603251
11.

CSF biomarkers for Alzheimer's Disease: levels of beta-amyloid, tau, phosphorylated tau relate to clinical symptoms and survival.

Wallin AK, Blennow K, Andreasen N, Minthon L.

Dement Geriatr Cogn Disord. 2006;21(3):131-8. Epub 2006 Jan 2.

PMID:
16391474
12.

Cerebrospinal fluid tau, phospho-tau181 and beta-amyloid1-42 in idiopathic normal pressure hydrocephalus: a discrimination from Alzheimer's disease.

Kapaki EN, Paraskevas GP, Tzerakis NG, Sfagos C, Seretis A, Kararizou E, Vassilopoulos D.

Eur J Neurol. 2007 Feb;14(2):168-73.

PMID:
17250725
13.

CSF total tau, Abeta42 and phosphorylated tau protein as biomarkers for Alzheimer's disease.

Blennow K, Vanmechelen E, Hampel H.

Mol Neurobiol. 2001 Aug-Dec;24(1-3):87-97. Review.

PMID:
11831556
14.

Additional use of Aβ₄₂/Aβ₄₀ ratio with cerebrospinal fluid biomarkers P-tau and Aβ₄₂ increases the level of evidence of Alzheimer's disease pathophysiological process in routine practice.

Sauvée M, DidierLaurent G, Latarche C, Escanyé MC, Olivier JL, Malaplate-Armand C.

J Alzheimers Dis. 2014;41(2):377-86. doi: 10.3233/JAD-131838.

PMID:
24614902
15.

Cost-effectiveness of the use of biomarkers in cerebrospinal fluid for Alzheimer's disease.

Valcárcel-Nazco C, Perestelo-Pérez L, Molinuevo JL, Mar J, Castilla I, Serrano-Aguilar P.

J Alzheimers Dis. 2014;42(3):777-88. doi: 10.3233/JAD-132216.

PMID:
24916543
16.

Clinical indications for analysis of Alzheimer's disease CSF biomarkers.

Engelborghs S.

Rev Neurol (Paris). 2013 Oct;169(10):709-14. doi: 10.1016/j.neurol.2013.07.024. Epub 2013 Sep 6. Review.

PMID:
24016466
17.

Comparison of two analytical platforms for the clinical qualification of Alzheimer's disease biomarkers in pathologically-confirmed dementia.

Le Bastard N, Coart E, Vanderstichele H, Vanmechelen E, Martin JJ, Engelborghs S.

J Alzheimers Dis. 2013;33(1):117-31. doi: 10.3233/JAD-2012-121246.

PMID:
22936010
18.

Evaluation of CSF-tau and CSF-Abeta42 as diagnostic markers for Alzheimer disease in clinical practice.

Andreasen N, Minthon L, Davidsson P, Vanmechelen E, Vanderstichele H, Winblad B, Blennow K.

Arch Neurol. 2001 Mar;58(3):373-9.

PMID:
11255440
19.

Addition of MHPG to Alzheimer's disease biomarkers improves differentiation of dementia with Lewy bodies from Alzheimer's disease but not other dementias.

Herbert MK, Aerts MB, Kuiperij HB, Claassen JA, Spies PE, Esselink RA, Bloem BR, Verbeek MM.

Alzheimers Dement. 2014 Jul;10(4):448-55.e2. doi: 10.1016/j.jalz.2013.05.1775. Epub 2013 Nov 13.

PMID:
24239248
20.

High cerebrospinal fluid tau and low amyloid beta42 levels in the clinical diagnosis of Alzheimer disease and relation to apolipoprotein E genotype.

Galasko D, Chang L, Motter R, Clark CM, Kaye J, Knopman D, Thomas R, Kholodenko D, Schenk D, Lieberburg I, Miller B, Green R, Basherad R, Kertiles L, Boss MA, Seubert P.

Arch Neurol. 1998 Jul;55(7):937-45.

PMID:
9678311

Supplemental Content

Support Center